Latest news with #SPRO
Yahoo
5 days ago
- Business
- Yahoo
Spero Therapeutics Inc (SPRO) Q2 2025 Earnings Call Highlights: Tepipenem HBR Trial Success and ...
Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points The phase 3 Pivot PO trial for tepipenem HBR in complicated urinary tract infections (CUTIs) met its primary endpoint and was stopped early for efficacy. Tepipenem HBR demonstrated non-inferiority to intravenous imipenem cilastatin in hospitalized adult patients with CUTIs, including pyelonephritis. The trial's early stopping for efficacy resulted in meaningful cost savings, extending Spero Therapeutics Inc (NASDAQ:SPRO)'s cash runway into 2028. Spero Therapeutics Inc (NASDAQ:SPRO) reported an increase in total revenue for Q2 2025 to $14.2 million, up from $10.2 million in Q2 2024, primarily due to collaboration revenue from GSK. The company achieved a significant reduction in R&D expenses, from $23.7 million in Q2 2024 to $10.7 million in Q2 2025, due to reduced clinical expenses related to the Pivot PO study. Negative Points The SPR 720 program did not meet its primary endpoint in a phase 2A proof of concept study for non-tuberculous mycobacterial pulmonary disease. Potential dose-limiting safety signals were observed in the SPR 720 study, including cases of reversible grade 3 hepatotoxicity. Spero Therapeutics Inc (NASDAQ:SPRO) reported a net loss of $1.7 million for Q2 2025, although this was an improvement from a $17.9 million loss in Q2 2024. General and administrative expenses increased to $5.9 million in Q2 2025 from $5.5 million in Q2 2024, primarily due to increased personnel and professional services expenses. The FDA action on the regulatory filing for tepipenem HBR is not expected until the second half of 2026, indicating a lengthy approval process. Q & A Highlights Warning! GuruFocus has detected 3 Warning Signs with SPRO. Q: How is Spero Therapeutics planning to allocate capital moving forward? Will the focus be on business development or pipeline expansion? A: (Unidentified_6) Our primary objective is to ensure that Tepipenem HBR gets through the regulatory process and achieves approval, as this will be the main value driver. Our current financial runway is designed to support this goal. Once we have a clearer path to approval, we will make further decisions regarding capital allocation. Q: Can you provide more details on the financial impact of the Pivot PO trial's early conclusion? A: (Esther Rajavello, CEO and CFO) The early conclusion of the Pivot PO trial for efficacy has resulted in significant cost savings, which we anticipate will extend our cash runway into 2028. This is primarily due to reduced clinical expenses as fewer patients were enrolled than initially planned. Q: What are the next steps for SPR 720 following the phase 2A trial results? A: (Tim Kreutzer, COO) The phase 2A trial for SPR 720 did not meet its primary endpoint, and we observed potential dose-limiting safety signals. We have completed the assessment of the full data set and are currently determining the next steps for the program. Q: What is the expected timeline for FDA action on Tepipenem HBR? A: (Esther Rajavello, CEO and CFO) We plan to work with GSK to include the Pivot PO data in an FDA filing by the end of 2025. We currently anticipate FDA action in the second half of 2026. Q: How does Spero Therapeutics view the market potential for Tepipenem HBR? A: (Tim Kreutzer, COO) We believe Tepipenem HBR has the potential to significantly impact the treatment landscape for complicated urinary tract infections (CUTIs) by offering an oral alternative to the standard IV carbapenem therapy. This could represent a major clinical advance and provide economic benefits to the healthcare system. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Globe and Mail
09-08-2025
- Business
- Globe and Mail
Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025
CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Tuesday August 12 th, 2025 at 4:30 p.m. ET to report financial results for second quarter 2025 and provide a business update. To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10200686, or click on this link and request a return call with passcode 0605709. The audio webcast can be accessed live on this link and also on the 'Investor Relations' page of the Spero Corporate Website at The archived webcast will also be available on Spero's website for 30 days following the call. About Spero Therapeutics Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with high unmet need. For more information, visit
Yahoo
28-06-2025
- Business
- Yahoo
While institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownership
Significant control over Spero Therapeutics by retail investors implies that the general public has more power to influence management and governance-related decisions A total of 25 investors have a majority stake in the company with 44% ownership Institutions own 20% of Spero Therapeutics Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Every investor in Spero Therapeutics, Inc. (NASDAQ:SPRO) should be aware of the most powerful shareholder groups. We can see that retail investors own the lion's share in the company with 54% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Meanwhile, institutions make up 20% of the company's shareholders. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. In the chart below, we zoom in on the different ownership groups of Spero Therapeutics. Check out our latest analysis for Spero Therapeutics Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. As you can see, institutional investors have a fair amount of stake in Spero Therapeutics. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Spero Therapeutics' earnings history below. Of course, the future is what really matters. Our data indicates that hedge funds own 6.8% of Spero Therapeutics. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. The company's largest shareholder is SR One Capital Management, LP, with ownership of 16%. In comparison, the second and third largest shareholders hold about 6.8% and 4.2% of the stock. A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority. While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. Shareholders would probably be interested to learn that insiders own shares in Spero Therapeutics, Inc.. As individuals, the insiders collectively own US$3.5m worth of the US$162m company. This shows at least some alignment, but we usually like to see larger insider holdings. You can click here to see if those insiders have been buying or selling. The general public -- including retail investors -- own 54% of Spero Therapeutics. This size of ownership gives investors from the general public some collective power. They can and probably do influence decisions on executive compensation, dividend policies and proposed business acquisitions. Private equity firms hold a 16% stake in Spero Therapeutics. This suggests they can be influential in key policy decisions. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public. It's always worth thinking about the different groups who own shares in a company. But to understand Spero Therapeutics better, we need to consider many other factors. Take risks for example - Spero Therapeutics has 3 warning signs (and 2 which can't be ignored) we think you should know about. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. — Investing narratives with Fair Values A case for TSXV:USA to reach USD $5.00 - $9.00 (CAD $7.30–$12.29) by 2029. By Agricola – Community Contributor Fair Value Estimated: CA$12.29 · 0.9% Overvalued DLocal's Future Growth Fueled by 35% Revenue and Profit Margin Boosts By WynnLevi – Community Contributor Fair Value Estimated: $195.39 · 0.9% Overvalued Historically Cheap, but the Margin of Safety Is Still Thin By Mandelman – Community Contributor Fair Value Estimated: SEK232.58 · 0.1% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
29-05-2025
- Business
- Yahoo
Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone
Spero Therapeutics, Inc. (NASDAQ:SPRO) saw its stock surge by 240% on May 28 following the company's announcement of the successful completion of the pivotal Phase 3 PIVOT-PO trial for tebipenem HBr, an investigational oral antibiotic intended for use in treating complicated urinary tract infections. The Phase 3 study, conducted in collaboration with development partner GSK plc, effectively achieved its primary goal, proving that tebipenem HBr is not inferior to the intravenous antibiotic imipenem-cilastatin in treating adult hospitalized patients with cUTI. According to a press statement issued by Spero on May 28, tebipenem HBr may be the first oral carbapenem antibiotic that patients in the U.S. can get, potentially addressing an estimated 2.9 million annual cases of cUTIs. The full trial results will be submitted to a peer-reviewed journal for publication and presentation at a later scientific convention, with Spero and GSK intending to submit the findings to the FDA in the second half of 2025. While we acknowledge the potential of SPRO to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SPRO and that has 100x upside potential, check out our report about the cheapest AI stock. Read More: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25-02-2025
- Business
- Yahoo
UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero's Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45th Annual Health Care Conference being held in Boston, March 3rd – 5th, 2025. Details are as follows: TD Cowen 45th Annual Health Care Conference Company presentation: Tuesday March 4, 2025 Time: 3:10 PM ET To request a meeting or for more details about the conferences please reach out to your institutional contact. The webcast may also be accessed through Spero Therapeutics' website ( on the 'Events and Presentations' page under the 'Connect' tab. A replay will be available on the website following the conclusion of the event. About Spero Therapeutics Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial more information, visit . Investor Relations Contact:Shai Biran, PhDSpero TherapeuticsIR@ Media Inquiries: media@
